Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.14
SARTF's Cash-to-Debt is ranked lower than
90% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.86 vs. SARTF: 0.14 )
Ranked among companies with meaningful Cash-to-Debt only.
SARTF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09  Med: 0.16 Max: No Debt
Current: 0.14
Equity-to-Asset 0.33
SARTF's Equity-to-Asset is ranked lower than
83% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. SARTF: 0.33 )
Ranked among companies with meaningful Equity-to-Asset only.
SARTF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.33 Max: 0.41
Current: 0.33
0.31
0.41
Interest Coverage 26.50
SARTF's Interest Coverage is ranked lower than
59% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.70 vs. SARTF: 26.50 )
Ranked among companies with meaningful Interest Coverage only.
SARTF' s Interest Coverage Range Over the Past 10 Years
Min: 1.7  Med: 6.91 Max: 26.57
Current: 26.5
1.7
26.57
Piotroski F-Score: 4
Altman Z-Score: 1.56
Beneish M-Score: -2.46
WACC vs ROIC
1.25%
14.04%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 16.64
SARTF's Operating Margin % is ranked higher than
84% of the 166 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.66 vs. SARTF: 16.64 )
Ranked among companies with meaningful Operating Margin % only.
SARTF' s Operating Margin % Range Over the Past 10 Years
Min: 3.97  Med: 11.02 Max: 17.25
Current: 16.64
3.97
17.25
Net Margin % 7.92
SARTF's Net Margin % is ranked higher than
75% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. SARTF: 7.92 )
Ranked among companies with meaningful Net Margin % only.
SARTF' s Net Margin % Range Over the Past 10 Years
Min: 0.16  Med: 5.71 Max: 11.33
Current: 7.92
0.16
11.33
ROE % 19.11
SARTF's ROE % is ranked higher than
60% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.21 vs. SARTF: 19.11 )
Ranked among companies with meaningful ROE % only.
SARTF' s ROE % Range Over the Past 10 Years
Min: 2.6  Med: 13.67 Max: 27.59
Current: 19.11
2.6
27.59
ROA % 6.36
SARTF's ROA % is ranked higher than
75% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. SARTF: 6.36 )
Ranked among companies with meaningful ROA % only.
SARTF' s ROA % Range Over the Past 10 Years
Min: 0.12  Med: 4.74 Max: 9.32
Current: 6.36
0.12
9.32
ROC (Joel Greenblatt) % 36.54
SARTF's ROC (Joel Greenblatt) % is ranked higher than
74% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. SARTF: 36.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SARTF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 13.32  Med: 34.32 Max: 48.51
Current: 36.54
13.32
48.51
3-Year Revenue Growth Rate 17.90
SARTF's 3-Year Revenue Growth Rate is ranked higher than
70% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. SARTF: 17.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SARTF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 6.45 Max: 17.9
Current: 17.9
0
17.9
3-Year EBITDA Growth Rate 26.20
SARTF's 3-Year EBITDA Growth Rate is ranked higher than
78% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. SARTF: 26.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SARTF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 3.6  Med: 16.2 Max: 32.5
Current: 26.2
3.6
32.5
3-Year EPS without NRI Growth Rate 28.90
SARTF's 3-Year EPS without NRI Growth Rate is ranked higher than
73% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. SARTF: 28.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SARTF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -36.7  Med: 23.2 Max: 87.3
Current: 28.9
-36.7
87.3
GuruFocus has detected 2 Warning Signs with Sartorius AG $SARTF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SARTF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with SARTF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research  
Compare:NYSE:BIO.B, NAS:ICLR, NYSE:CRL, NYSE:PKI, NAS:BRKR, NAS:VWR, NAS:PRAH, NAS:QGEN, NAS:DXCM, OTCPK:CZMWY, NYSE:ALR, NAS:PRXL, OTCPK:ERFSF, NAS:NEOG, NAS:INCR, NAS:EXAS, NAS:MYGN, NAS:AXDX, NAS:FMI, NAS:VREX » details
Traded in other countries:SRT3.Germany, SRT3.Switzerland, 0NIR.UK,
Sartorius AG provides laboratory and process technologies and equipment for biopharmaceutical production and laboratory environments. It focuses on two division : Bioprocess Solution and Lab Products & Services.

Sartorius AG provides laboratory and process technologies and equipment that is used in biopharmaceutical production and laboratory environments. It caters to biotech, pharmaceutical and food industries, and public research institutes and laboratories.

Ratios

vs
industry
vs
history
PE Ratio 50.87
SARTF's PE Ratio is ranked lower than
76% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.02 vs. SARTF: 50.87 )
Ranked among companies with meaningful PE Ratio only.
SARTF' s PE Ratio Range Over the Past 10 Years
Min: 3.77  Med: 27.65 Max: 53.3
Current: 50.87
3.77
53.3
PE Ratio without NRI 50.87
SARTF's PE Ratio without NRI is ranked lower than
76% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.50 vs. SARTF: 50.87 )
Ranked among companies with meaningful PE Ratio without NRI only.
SARTF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 3.78  Med: 28.17 Max: 63.31
Current: 50.87
3.78
63.31
PB Ratio 9.00
SARTF's PB Ratio is ranked lower than
88% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.55 vs. SARTF: 9.00 )
Ranked among companies with meaningful PB Ratio only.
SARTF' s PB Ratio Range Over the Past 10 Years
Min: 0.91  Med: 4.15 Max: 10.37
Current: 9
0.91
10.37
PS Ratio 4.02
SARTF's PS Ratio is ranked lower than
60% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. SARTF: 4.02 )
Ranked among companies with meaningful PS Ratio only.
SARTF' s PS Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.65 Max: 4.79
Current: 4.02
0.4
4.79
Price-to-Free-Cash-Flow 244.55
SARTF's Price-to-Free-Cash-Flow is ranked lower than
99.99% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.34 vs. SARTF: 244.55 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SARTF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 2.05  Med: 48.58 Max: 487.57
Current: 244.55
2.05
487.57
Price-to-Operating-Cash-Flow 30.72
SARTF's Price-to-Operating-Cash-Flow is ranked lower than
79% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.21 vs. SARTF: 30.72 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SARTF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.7  Med: 14.52 Max: 44.68
Current: 30.72
1.7
44.68
EV-to-EBIT 5.54
SARTF's EV-to-EBIT is ranked lower than
67% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.46 vs. SARTF: 5.54 )
Ranked among companies with meaningful EV-to-EBIT only.
SARTF' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.54  Med: 19.1 Max: 52.7
Current: 5.54
5.54
52.7
EV-to-EBITDA 4.06
SARTF's EV-to-EBITDA is ranked lower than
67% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.84 vs. SARTF: 4.06 )
Ranked among companies with meaningful EV-to-EBITDA only.
SARTF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.06  Med: 11.3 Max: 25.9
Current: 4.06
4.06
25.9
PEG Ratio 2.72
SARTF's PEG Ratio is ranked lower than
61% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. SARTF: 2.72 )
Ranked among companies with meaningful PEG Ratio only.
SARTF' s PEG Ratio Range Over the Past 10 Years
Min: 0.31  Med: 2.48 Max: 5.28
Current: 2.72
0.31
5.28
Current Ratio 1.61
SARTF's Current Ratio is ranked lower than
64% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. SARTF: 1.61 )
Ranked among companies with meaningful Current Ratio only.
SARTF' s Current Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.35 Max: 1.76
Current: 1.61
0.87
1.76
Quick Ratio 1.00
SARTF's Quick Ratio is ranked lower than
78% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. SARTF: 1.00 )
Ranked among companies with meaningful Quick Ratio only.
SARTF' s Quick Ratio Range Over the Past 10 Years
Min: 0.58  Med: 0.85 Max: 1.17
Current: 1
0.58
1.17
Days Inventory 116.49
SARTF's Days Inventory is ranked lower than
65% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.88 vs. SARTF: 116.49 )
Ranked among companies with meaningful Days Inventory only.
SARTF' s Days Inventory Range Over the Past 10 Years
Min: 77.84  Med: 99.52 Max: 118.94
Current: 116.49
77.84
118.94
Days Sales Outstanding 67.72
SARTF's Days Sales Outstanding is ranked lower than
60% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 61.18 vs. SARTF: 67.72 )
Ranked among companies with meaningful Days Sales Outstanding only.
SARTF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.31  Med: 60.35 Max: 81.63
Current: 67.72
50.31
81.63
Days Payable 65.72
SARTF's Days Payable is ranked higher than
65% of the 135 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. SARTF: 65.72 )
Ranked among companies with meaningful Days Payable only.
SARTF' s Days Payable Range Over the Past 10 Years
Min: 46.73  Med: 67.84 Max: 75.73
Current: 65.72
46.73
75.73

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.48
SARTF's Dividend Yield % is ranked lower than
74% of the 95 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.05 vs. SARTF: 0.48 )
Ranked among companies with meaningful Dividend Yield % only.
SARTF' s Dividend Yield % Range Over the Past 10 Years
Min: 0.34  Med: 1.07 Max: 23.57
Current: 0.48
0.34
23.57
Dividend Payout Ratio 0.25
SARTF's Dividend Payout Ratio is ranked higher than
63% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.25 vs. SARTF: 0.25 )
Ranked among companies with meaningful Dividend Payout Ratio only.
SARTF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.16  Med: 0.28 Max: 0.93
Current: 0.25
0.16
0.93
3-Year Dividend Growth Rate 16.90
SARTF's 3-Year Dividend Growth Rate is ranked lower than
59% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.30 vs. SARTF: 16.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
SARTF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: -1.55 Max: 47
Current: 16.9
0
47
Forward Dividend Yield % 0.48
SARTF's Forward Dividend Yield % is ranked lower than
73% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.09 vs. SARTF: 0.48 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.05
SARTF's 5-Year Yield-on-Cost % is ranked higher than
64% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. SARTF: 1.05 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
SARTF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.75  Med: 2.35 Max: 51.68
Current: 1.05
0.75
51.68
3-Year Average Share Buyback Ratio -0.10
SARTF's 3-Year Average Share Buyback Ratio is ranked higher than
83% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. SARTF: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SARTF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.1  Med: 0 Max: 0
Current: -0.1
-0.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 6.84
SARTF's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
84% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. SARTF: 6.84 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SARTF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.1  Med: 0.23 Max: 6.84
Current: 6.84
0.1
6.84
Price-to-Median-PS-Value 2.44
SARTF's Price-to-Median-PS-Value is ranked lower than
89% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. SARTF: 2.44 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SARTF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 0.44 Max: 2.9
Current: 2.44
0.05
2.9
Price-to-Peter-Lynch-Fair-Value 2.86
SARTF's Price-to-Peter-Lynch-Fair-Value is ranked lower than
72% of the 25 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.77 vs. SARTF: 2.86 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
SARTF' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.11  Med: 0.32 Max: 5.15
Current: 2.86
0.11
5.15
Earnings Yield (Greenblatt) % 18.05
SARTF's Earnings Yield (Greenblatt) % is ranked higher than
68% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.78 vs. SARTF: 18.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SARTF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.9  Med: 5.2 Max: 18.05
Current: 18.05
1.9
18.05
Forward Rate of Return (Yacktman) % 18.20
SARTF's Forward Rate of Return (Yacktman) % is ranked higher than
76% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.41 vs. SARTF: 18.20 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
SARTF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -12.7  Med: 18.25 Max: 91.2
Current: 18.2
-12.7
91.2

More Statistics

Revenue (TTM) (Mil) $1,435
EPS (TTM) $ 1.66
Beta-0.76
Short Percentage of Float0.00%
52-Week Range $68.65 - 89.00
Shares Outstanding (Mil)68.39
» More Articles for SARTF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)